Amarin Falls After U.S. Approval Limits Debut Drug’s Use

U.S. approval for Amarin Corp.’s first product, a drug to combat high levels of blood fat that can lead to stroke and heart attack, included limits on its use that may have disappointed investors.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.